Repaglinide and Rifampin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Repaglinide (repaglinide) and Rifampin (rifampin). Common drug interactions include subcutaneous abscess among females and interstitial lung disease among males.

The phase IV clinical study analyzes what interactions people have when they take Repaglinide and Rifampin. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 8,226 Repaglinide users. Check the latest studies of Repaglinide.

What is Rifampin?

Rifampin has active ingredients of rifampin. It is often used in tuberculosis. eHealthMe is studying from 12,339 Rifampin users. Check the latest studies of Rifampin.



On Jul, 10, 2026

14 people who take Repaglinide and Rifampin together, and have interactions are studied.

Repaglinide and Rifampin drug interactions.

What are the common drug interactions of Repaglinide and Rifampin, by gender? *:

female:

  1. Subcutaneous abscess
  2. Ankylosing spondylitis (type of arthritis affecting the spine)
  3. Coagulopathy (blood's ability to clot is impaired)
  4. Device related infection
  5. Haematoma (collection of blood outside the blood vessels)
  6. Neutropenia (an abnormally low number of neutrophils)

male:

  1. Interstitial lung disease
  2. Abscess (pus)
  3. Palpitations (feelings or sensations that your heart is pounding or racing)
  4. Acute myocardial infarction (acute heart attack)
  5. Drug administration error
  6. Drug resistance (reduction in effectiveness of a drug)
  7. Fistula (an abnormal connection or passageway between two)
  8. Nodule (a growth of abnormal tissue)
  9. Pain
  10. Corneal deposits

What are the common drug interactions of Repaglinide and Rifampin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Corneal deposits
  2. Drug administration error
  3. Drug level below therapeutic
  4. Halo vision (rainbow vision)
  5. Palpitations (feelings or sensations that your heart is pounding or racing)

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Interstitial lung disease
  2. Subcutaneous abscess
  3. Neutropenia (an abnormally low number of neutrophils)
  4. Palpitations (feelings or sensations that your heart is pounding or racing)
  5. Acute myocardial infarction (acute heart attack)
  6. Ankylosing spondylitis (type of arthritis affecting the spine)
  7. Coagulopathy (blood's ability to clot is impaired)
  8. Corneal deposits
  9. Device related infection
  10. Drug level below therapeutic

What are the existing conditions these people have? *

  1. Staphylococcal Infection (an infection with staphylococcus bacteria): 5 people, 35.71%
  2. Type 2 Diabetes: 3 people, 21.43%
  3. Liver Disorder (liver diseases): 3 people, 21.43%
  4. Hidradenitis (chronic disease of a type of sweat gland): 3 people, 21.43%
  5. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 14.29%
  6. Osteomyelitis (infection of bone): 1 person, 7.14%
  7. Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 1 person, 7.14%
  8. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 7.14%
  9. Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 7.14%
  10. Endocarditis (inflammation in heart muscle): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Repaglinide and Rifampin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Repaglinide and Rifampin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Repaglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Rifampin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Repaglinide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rifampin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on repaglinide and rifampin (the active ingredients of Repaglinide and Rifampin, respectively), and Repaglinide and Rifampin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: